CEO Peter Dolan

CEO Peter Dolan

CEO Peter Dolan has been the chief executive officer of Bristol-Myers Squibb Co since 2001. He is 50 years old. Follow Mr. Dolan and Bristol-Myers Squibb Co in the news and blogs or share your own opinion about the company and its... [more]

CEO Peter Dolan has been the chief executive officer of Bristol-Myers Squibb Co since 2001. He is 50 years old. Follow Mr. Dolan and Bristol-Myers Squibb Co in the news and blogs or share your own opinion about the company and its leadership.

Sorted by: Top Rated
No pictures yet.
AP - Like other major drugmakers, Bristol-Myers Squibb Co. and Eli Lilly & Co. saw benefits from the weak dollar in the second quarter, as sales grew at a faster rate overseas, but both also posted improvements in their U.S. businesses.  
From news.yahoo.com ()
Related news:
More perspectives...
Like other major drugmakers, Bristol-Myers Squibb Co. and Eli Lilly & Co. saw benefits from the weak dollar in the second quarter, as sales grew at a faster rate overseas, but both also posted improvements in ...  
From rss.topix.net via Topix. ()
Related news:
More perspectives...
NEW YORK (Reuters) - Bristol-Myers Squibb Co, which sells leading blood clot preventer Plavix, on Thursday dismissed Eli Lilly and Co's rival Effient drug as a "niche" product that has harmed or failed to help three groups of patients in a big study.  
From reuters.com ()
Related news:
More perspectives...
Drugmaker Bristol-Myers Squibb Co. on Thursday reported an 8 percent increase in second-quarter profit, beating Wall Street expectations, as the weak dollar boosted foreign sales and several key drugs saw big ...  
From rss.topix.net via Topix. ()
Related news:
More perspectives...
Drugmaker Bristol-Myers Squibb Co. on Thursday reported an 8 percent increase in second-quarter profit, beating Wall Street expectations, as the weak dollar boosted foreign sales and several key drugs saw big ...  
From rss.topix.net via Topix. ()
Related news:
More perspectives...
Eli Lilly & Co. 's profit jumped 44 percent and Bristol-Myers Squibb Co. earnings rose 23 percent, boosted by sales of psychiatric medicines and the weak dollar.  
From topix.com via Topix. ()
More perspectives...
New York (aktiencheck.de AG) - Der US-Pharmakonzern Bristol-Myers Squibb Co. (ISIN US1101221083/ WKN 850501) konnte im zweiten Quartal 2008 seinen Gewinn vergrö֟ern. Wie das Unternehmen am Donnerstag verkündete, kletterten die Umsatzerlöse auf 5,2  
From ad-hoc-news.de ()
Related news:
More perspectives...
July 24 (Bloomberg) -- Eli Lilly & Co. 's profit jumped 44 percent and Bristol-Myers Squibb Co. earnings rose 23 percent, boosted by sales of psychiatric medicines and the weak dollar. ImClone reported that sales of the cancer therapy Erbitux, which ...  
From search.msn.com ()
More perspectives...
Bristol-Myers Squibb has agreed to pay Washington state nearly $7 million to settle allegations of illegal marketing and pricing of prescription medications.  
From seattletimes.nwsource.com ()
Related news:
More perspectives...
Bristol-Myers Squibb Co. 's profit jumped 23 percent on rising sales of its blood thinner Plavix and mood-stabilizer Abilify.  
From rss.topix.net via Topix. ()
Related news:
More perspectives...
No entries yet.
Sponsors
Sorted by: Top Picks
 
Written by Drich on
 
Written by yudhis97 on
 
Written by richardonecare on
 
Written by nautical4 on
 

More From Zimbio
Copyright © 2008 - Zimbio, Inc. Some rights reserved.